#01#
Revisiones
(todas) *** Reviews (all)
INMUNOSUPRESIÓN
*** IMMUNOSUPPRESSION
(Conceptos
/ Keywords: Immunosuppression; Immunosuppressive ag.; Transpl. immunol.; GVH;
Antirejection therapy; Lymphocyte depletion; Transpl. conditioning; etc).
Enero /
January 2001 --- Marzo / March 2004
La
biblioteca del conocimiento biomédico© es un servicio GRATUITO. Toda la
información ha sido obtenida de fuentes públicas, de portales de internet que
no requieren registro alguno para su uso, que no requieren estar de acuerdo con
sus Términos de uso, que son de libre acceso a todo el mundo, y son a su vez
gratuitos. La biblioteca (revisiones, guías, protocolos, medicina basada en la
evidencia, etc...) se recopila en base a una patente que permite a Effiloop la
catalogación de los artículos por campos de interés así como por el orden de su
importancia (se proveen las primeras 200 revisiones). Toda la informacion se
ampara en las leyes de libre pensamiento-expresión, y de uso justo. Este
documento sólo contiene artículos escritos en Castellano y/o Inglés.
The
biomedical library© is a FREE service. All the information has been obtained
from public sources, from web sites that do not require registration for their
use, that do not require an agreement with their Terms of use, that provide
free access for all, and are free of charge. The library (reviews, guides,
protocols, medicine based medicine, etc) is arranged according to a patent that
warrants Effiloop to catalogue the articles by fields of interest as well as to
sort articles by true relevance (the first 200 reviews are provided). All the
information is provided according to the freedom of speech and fair use laws.
Only articles written in Spanish and/or English are included.
[1]
TÍTULO / TITLE: - Hepcidin: a putative
iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia
of chronic disease.
REVISTA
/ JOURNAL: - Proc Natl Acad Sci U S A. Acceso gratuito
al texto completo a partir de los 6 meses de la fecha de publicación.
●●
Enlace a la Editora de la Revista http://www.pnas.org/
●●
Cita: Proc Natl Acad Sci USA (PNAS): <> 2001 Jul 17;98(15):8160-2.
●●
Enlace al texto completo (gratuito o de pago) 1073/pnas.161296298
AUTORES
/ AUTHORS: - Fleming RE; Sly WS
INSTITUCIÓN
/ INSTITUTION: - Department of Pediatrics, Saint Louis
University School of Medicine, St. Louis, MO 63014, USA. N. Ref:: 30
----------------------------------------------------
[2]
TÍTULO / TITLE: - Beta lactam monotherapy
versus beta lactam-aminoglycoside combination therapy for sepsis in
immunocompetent patients: systematic review and meta-analysis of randomised
trials.
REVISTA
/ JOURNAL: - British Medical J (BMJ). Acceso gratuito
al texto completo.
●●
Enlace a la Editora de la Revista http://bmj.com/search.dtl
●●
Cita: British Medical J. (BMJ): <> 2004 Mar 20;328(7441):668. Epub 2004
Mar 2.
●●
Enlace al texto completo (gratuito o de pago) 1136/bmj.38028.520995.63
AUTORES
/ AUTHORS: - Paul M; Benuri-Silbiger I; Soares-Weiser K;
Leibovici L
INSTITUCIÓN
/ INSTITUTION: - Department of Medicine E and Infectious
Diseases Unit, Rabin Medical Centre, Beilinson Campus, Petah-Tikva 49100,
Israel. mica@zahav.net.il
RESUMEN
/ SUMMARY: - OBJECTIVE: To compare beta lactam
monotherapy with beta lactam-aminoglycoside combination therapy for severe
infections. DATA SOURCES: Medline, Embase, Lilacs, Cochrane Library, and
conference proceedings, to 2003; references of included studies; contact with all
authors. No restrictions, such as language, year of publication, or publication
status. STUDY SELECTION: All randomised trials of beta lactam monotherapy
compared with beta lactam-aminoglycoside combination therapy for patients
without neutropenia who fulfilled criteria for sepsis. DATA SELECTION: Two
reviewers independently applied selection criteria, performed quality
assessment, and extracted the data. The primary outcome assessed was all cause
fatality by intention to treat. Relative risks were pooled with the random
effect model (relative risk < 1 favours monotherapy). RESULTS: 64 trials
with 7586 patients were included. There was no difference in all cause fatality
(relative risk 0.90, 95% confidence interval 0.77 to 1.06). 12 studies compared
the same beta lactam (1.02, 0.76 to 1.38), and 31 studies compared different
beta lactams (0.85, 0.69 to 1.05). Clinical failure was more common with
combination treatment overall (0.87, 0.78 to 0.97) and among studies comparing
different beta lactams (0.76, 0.68 to 0.86). There was no advantage to
combination therapy among patients with Gram negative infections (1835
patients) or Pseudomonas aeruginosa infections (426 patients). There was no
difference in the rate of development of resistance. Nephrotoxicity was significantly
more common with combination therapy (0.36, 0.28 to 0.47). Heterogeneity was
not significant for these comparisons. CONCLUSIONS: In the treatment of sepsis
the addition of an aminoglycoside to beta lactams should be discouraged.
Fatality remains unchanged, while the risk for adverse events is
increased. N. Ref:: 26
----------------------------------------------------
[3]
TÍTULO / TITLE: - Immunopathogenesis and
immunotherapy in AIDS virus infections.
REVISTA
/ JOURNAL: - Nat Med 2003 Jul;9(7):861-6.
●●
Enlace al texto completo (gratuito o de pago) 1038/nm0703-861
AUTORES
/ AUTHORS: - Letvin NL; Walker BD
INSTITUCIÓN
/ INSTITUTION: - Division of Viral Pathogenesis, Beth
Israel Deaconess Medical Center, Massachusetts General Hospital, Harvard
Medical School, Boston, Massachusetts 02114, USA.
RESUMEN
/ SUMMARY: - The heterogeneity of HIV and the different
human leukocyte antigen (HLA) backgrounds of infected individuals have posed
challenges to understanding the pathogenesis of HIV infection. But continuing
advances in our knowledge of the role of immune responses in controlling HIV
viremia should help to define goals for immune-based therapies and vaccine
strategies against AIDS. N.
Ref:: 106
----------------------------------------------------
[4]
TÍTULO / TITLE: - Integration of growth
factor and nutrient signaling: implications for cancer biology.
REVISTA
/ JOURNAL: - Mol Cell 2003 Aug;12(2):271-80.
AUTORES
/ AUTHORS: - Shamji AF; Nghiem P; Schreiber SL
INSTITUCIÓN
/ INSTITUTION: - Harvard Biophysics Program, Harvard
University, 12 Oxford Street, Cambridge, MA 02138, USA.
RESUMEN
/ SUMMARY: - Signaling networks that promote cell
growth are frequently dysregulated in cancer. One regulatory network, which
converges on effectors such as 4EBP1 and S6K1, leads to growth by promoting
protein synthesis. Here, we discuss how this network is regulated by both
extracellular signals, such as growth factors, and intracellular signals, such
as nutrients. We discuss how mutations amplifying either type of signal can
lead to tumor formation. In particular, we focus on the recent discovery that a
tumor suppressor complex whose function is lost in tuberous sclerosis patients
regulates the nutrient signal carried by the critical signaling protein TOR to
the effectors 4EBP1 and S6K1. Finally, we describe how the small molecule
rapamycin, which inhibits TOR and thereby the activation of these effectors,
could be useful to treat tumors that have become dependent upon this pathway
for growth. N. Ref:: 80
----------------------------------------------------
[5]
TÍTULO / TITLE: - Defying death—HIV
mutation to evade cytotoxic T lymphocytes.
REVISTA
/ JOURNAL: - N Engl J Med. Acceso gratuito al texto
completo a partir de los 6 meses de la fecha de publicación.
●●
Enlace a la Editora de la Revista http://content.nejm.org/
●●
Cita: New England J Medicine (NEJM): <> 2002 Oct 10;347(15):1203-4.
●●
Enlace al texto completo (gratuito o de pago) 1056/NEJMcibr022067
AUTORES
/ AUTHORS: - Lieberman J
INSTITUCIÓN
/ INSTITUTION: - Center for Blood Research, Boston, MA
02115, USA. N. Ref:: 5
----------------------------------------------------
[6]
TÍTULO / TITLE: - Genetic and functional
relationships between MHC and NK receptor genes.
REVISTA
/ JOURNAL: - Immunity 2001 Sep;15(3):363-74.
AUTORES
/ AUTHORS: - Trowsdale J
INSTITUCIÓN
/ INSTITUTION: - Immunology Division, Pathology Department,
University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United Kingdom.
RESUMEN
/ SUMMARY: - HLA class I and NK receptors are encoded
within dense clusters of immune loci. The MHC, at 6p21.3, and the complex
containing the KIR loci, at 19q13.4, both feature variation in the number of
genes, as well as sequence polymorphism. In addition to T cell receptors,
several variable class I-related molecules interact with polymorphic NK
receptors. Some of the lectin-related NK receptor genes, at 12p13.1, also have
ligands belonging to the extended class I family. The expanding clusters of
class I-related sequences and their receptors, some of which evolved recently,
reveal further complexity in immune recognition of disease. N. Ref:: 85
----------------------------------------------------
[7]
TÍTULO / TITLE: - Dendritic cells:
emerging pharmacological targets of immunosuppressive drugs.
REVISTA
/ JOURNAL: - Nat Rev Immunol 2004 Jan;4(1):24-34.
●●
Enlace al texto completo (gratuito o de pago) 1038/nri1256
AUTORES
/ AUTHORS: - Hackstein H; Thomson AW
INSTITUCIÓN
/ INSTITUTION: - Institute for Clinical Immunology and
Transfusion Medicine, Justus-Liebig University Giessen, Langhansstr. 7, D-35392
Giessen, Germany. holger.hackstein@immunologie.med.uni-giessen.de
RESUMEN
/ SUMMARY: - Immunosuppressive drugs have
revolutionized organ transplantation and improved the therapeutic management of
autoimmune diseases. The development of immunosuppressive drugs and
understanding of their action traditionally has been focused on lymphocytes,
but recent evidence indicates that these agents interfere with immune responses
at the earliest stage, targeting key functions of dendritic cells (DCs). Here,
we review our present understanding of how classical and new immunosuppressive
agents interfere with DC development and function. This knowledge might provide
a rational basis for the selection of immunosuppressive drugs in different
clinical settings and for the generation of tolerogenic DCs in the
laboratory. N. Ref:: 116
----------------------------------------------------
[8]
TÍTULO / TITLE: - Impact of shared
epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240
rheumatoid arthritis patients.
REVISTA
/ JOURNAL: - Arthritis Rheum 2004 Feb;50(2):400-12.
●●
Enlace al texto completo (gratuito o de pago) 1002/art.20006
AUTORES
/ AUTHORS: - Gorman JD; Lum RF; Chen JJ; Suarez-Almazor
ME; Thomson G; Criswell LA
INSTITUCIÓN
/ INSTITUTION: - University of California, San Francisco,
CA 94143-0500, USA. lac@itsa.ucsf.edu
RESUMEN
/ SUMMARY: - OBJECTIVE: The strongest known genetic
association in rheumatoid arthritis (RA) is with HLA-DRB1 alleles that share a
similar amino acid sequence, termed the shared epitope (SE). Although many studies
have examined the association of the SE with disease severity, the results have
been inconsistent, which may reflect the relatively small sample sizes or
ethnic differences. The aim of this study was to assess the association of
HLA-DRB1 SE alleles and genotype with the development of bony erosions in RA by
meta-analysis. METHODS: We identified English-language articles published
between January 1, 1987 and June 1, 1999 through Medline, EMBase, and manual
searches of 6 relevant journals. Included were studies in which molecular
typing of HLA-DRB1 alleles was performed and in which the presence or absence
of bony erosions was reported. Data were extracted from the studies, and
erosions were coded as present or absent. Authors were contacted for missing information
and data on individual patients. RESULTS: A total of 29 studies and 3,240
patients were available for analysis. The summary odds ratios (ORs), when all
patients were evaluated as a single group, demonstrated a significant
association of the presence of the SE (2 or 1 versus 0 SE alleles) with
erosions (OR 2.0; 95% confidence interval [95% CI] 1.8-2.2), although
significant heterogeneity was present (P = 0.002). Subgroup analyses
demonstrated the important influence of ethnic background. For example, no
association of the SE with erosions was demonstrated in Greeks (OR 0.8 [95% CI
0.2-1.5]). In contrast, there was a striking dose-dependent relationship in
southern European Caucasians and Asians, with ORs as high as 6.2 and 5.4,
respectively, in patients with 2 SE alleles. Although our ability to assess the
relationship between SE genotype and erosions was limited, particular
importance of the DRB1*0401 SE allele was suggested in an analysis restricted
to northern European Caucasians. CONCLUSION: The SE is associated with the
development of erosive disease in many ethnic groups; however, striking
exceptions exist. These variations may be due to allele differences between
populations, such as the frequency of DRB1*0401 among different ethnic groups.
Further study to better understand the genetic and environmental differences
between these populations may provide insight into mechanisms that influence
the clinical expression of RA.
----------------------------------------------------
[9]
TÍTULO / TITLE: - Routes to transplant
tolerance versus rejection; the role of cytokines.
REVISTA
/ JOURNAL: - Immunity 2004 Feb;20(2):121-31.
AUTORES
/ AUTHORS: - Walsh PT; Strom TB; Turka LA
INSTITUCIÓN
/ INSTITUTION: - University of Pennsylvania, 700 Clinical
Research Building, 415 Curie Boulevard, Philadelphia, PA 19104, USA.
RESUMEN
/ SUMMARY: - The alloimmune response can be divided
into specific junctures where critical decisions between tolerance and immunity
are made which define the outcome of the transplant. At these “decision nodes”
various cytokines direct alloresponsive T cells to develop either a
proinflammatory response aimed at graft destruction or an immunoregulatory
response facilitating graft acceptance. This review will focus on the role of
these cytokines in influencing the progression of an alloimmune response
leading ultimately to either allograft survival or rejection. N. Ref:: 97
----------------------------------------------------
[10]
TÍTULO / TITLE: - Microchimerism: an
investigative frontier in autoimmunity and transplantation.
REVISTA
/ JOURNAL: - JAMA. Acceso gratuito al texto completo.
●●
Enlace a la Editora de la Revista http://jama.ama-assn.org/search.dtl
●●
Cita: JAMA: <> 2004 Mar 3;291(9):1127-31.
●●
Enlace al texto completo (gratuito o de pago) 1001/jama.291.9.1127
AUTORES
/ AUTHORS: - Adams KM; Nelson JL
INSTITUCIÓN
/ INSTITUTION: - Program in Human Immunogenetics, Clinical
Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
98109-1024, USA.
RESUMEN
/ SUMMARY: - Recent studies indicate cells transfer
between fetus and mother during pregnancy and can persist in both decades
later. The presence within one individual of a small population of cells from
another genetically distinct individual is referred to as microchimerism.
Naturally acquired microchimerism has recently been investigated in autoimmune
diseases, including scleroderma, thyroiditis, primary biliary cirrhosis,
Sjogren syndrome, systemic lupus, dermatomyositis, and neonatal lupus. Iatrogenic
chimerism has been investigated in transplantation and following blood
transfusion. Considering findings of naturally acquired microchimerism along
with iatrogenic microchimerism suggests microchimerism can have detrimental
and/or beneficial effects in both settings. Recent identification of
tissue-specific microchimerism either from naturally acquired or iatrogenic
microchimerism (eg, cardiac myocytes) raises the possibility that
microchimerism can be a target of autoimmunity or alternatively contribute to
tissue repair. Advances in this new frontier of research with varied and
numerous implications for human health are summarized. N. Ref:: 26
----------------------------------------------------
[11]
TÍTULO / TITLE: - The allogeneic response
and tumor immunity.
REVISTA
/ JOURNAL: - Nat Med 2001 Jun;7(6):649-52.
●●
Enlace al texto completo (gratuito o de pago) 1038/89008
AUTORES
/ AUTHORS: - Fabre JW
INSTITUCIÓN
/ INSTITUTION: - Department of Clinical Sciences, Institute
of Liver Studies Guy’s, King’s and St Thomas’ School of Medicine, London, UK. john.fabre@kcl.ac.uk
RESUMEN
/ SUMMARY: - The strong allogeneic response to donor
MHC molecules in transplantation and the weak response to tumor antigens
represent two important and divergent but potentially interactive immune
responses. A patient’s response to allogeneic MHC molecules might promote an
effective T-cell response to self MHC-restricted tumor peptides and the
possibilities for this are discussed here. These allogeneic responses might
successfully be harnessed to promote the immune eradication of metastatic
cancer. N. Ref:: 45
----------------------------------------------------
[12]
TÍTULO / TITLE: - A review of activity
indices and efficacy endpoints for clinical trials of medical therapy in adults
with Crohn’s disease.
REVISTA
/ JOURNAL: - Gastroenterology 2002 Feb;122(2):512-30.
AUTORES
/ AUTHORS: - Sandborn WJ; Feagan BG; Hanauer SB; Lochs
H; Lofberg R; Modigliani R; Present DH; Rutgeerts P; Scholmerich J; Stange EF;
Sutherland LR
INSTITUCIÓN
/ INSTITUTION: - The Clinical Trials Task Force of the
International Organization of Inflammatory Bowel Disease. sandborn.william@mayo.edu N. Ref:: 115
----------------------------------------------------
[13]
TÍTULO / TITLE: - Skin cancers after
organ transplantation.
REVISTA
/ JOURNAL: - N Engl J Med. Acceso gratuito al texto
completo a partir de los 6 meses de la fecha de publicación.
●●
Enlace a la Editora de la Revista http://content.nejm.org/
●●
Cita: New England J Medicine (NEJM): <> 2003 Apr 24;348(17):1681-91.
●●
Enlace al texto completo (gratuito o de pago) 1056/NEJMra022137
AUTORES
/ AUTHORS: - Euvrard S; Kanitakis J; Claudy A
INSTITUCIÓN
/ INSTITUTION: - Department of Dermatology, Edouard Herriot
Hospital, Lyons, France. sylvie.euvrard@numericable.fr N. Ref:: 100
----------------------------------------------------
[14]
TÍTULO / TITLE: - Haematopoietic cell
transplantation as immunotherapy.
REVISTA
/ JOURNAL: - Nature 2001 May 17;411(6835):385-9.
●●
Enlace al texto completo (gratuito o de pago) 1038/35077251
AUTORES
/ AUTHORS: - Appelbaum FR
INSTITUCIÓN
/ INSTITUTION: - Clinical Research Division, Fred
Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-310, PO Box
19024, Seattle, Washington 98109-1024, USA.
RESUMEN
/ SUMMARY: - The graft-versus-tumour effect seen after
allogeneic (genetically different) haematopoietic cell transplantation for
human malignancies represents the clearest example of the power of the human
immune system to eradicate cancer. Recent advances in our understanding of the
immunobiology of stem-cell engraftment, tolerance and tumour eradication are
allowing clinicians to better harness this powerful effect. N. Ref:: 60
----------------------------------------------------
[15]
TÍTULO / TITLE: - Lack of association of
the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data
meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis.
REVISTA
/ JOURNAL: - Arthritis Rheum 2004 Mar;50(3):753-62.
●●
Enlace al texto completo (gratuito o de pago) 1002/art.20119
AUTORES
/ AUTHORS: - Gorman JD; David-Vaudey E; Pai M; Lum RF;
Criswell LA
INSTITUCIÓN
/ INSTITUTION: - University of California, San Francisco,
and School of Public Health, University of California, Berkeley.
RESUMEN
/ SUMMARY: - OBJECTIVE: The objective of this
individual patient data (IPD) meta-analysis was to examine the relationship of
rheumatoid nodules to the HLA-DRB1 shared epitope (SE) and to individual SE
genotypes. METHODS: English-language studies that enrolled adult non-Hispanic
Caucasian patients with rheumatoid arthritis (RA) were identified by searches
of Medline and Embase, and by manual searches of medical journals. All authors
were contacted for IPD. Meta-analysis was performed to assess the association
of SE presence, dose, and genotype with rheumatoid nodules. Meta-analyses
adjusted for disease duration and cumulative meta-analyses were also performed
to assess the influence of RA duration and year of study publication on the
results. RESULTS: A total of 24 studies and 3,272 patients were available for
analysis. IPD were obtained for 22 of the studies. There was a nonsignificant
association between the presence of the SE (i.e., 1 or 2 alleles versus 0
alleles) and rheumatoid nodules (summary odds ratio [OR] 1.3, 95% confidence
interval [95% CI] 0.97-1.6). Analysis by SE genotype, however, demonstrated a
weak relationship with inheritance of a single DRB1*0401 SE allele (OR 1.4, 95%
CI 1.1-1.8). No other genotypes achieved statistical significance in the
adjusted or unadjusted analyses. CONCLUSION: The presence of the HLA-DRB1 SE
does not appear to significantly increase the risk of rheumatoid nodules among
Caucasian patients with RA. Analysis by DRB1 SE genotype was uninformative,
suggesting only a potential (and at most modest) role of the DRB1*0401 SE
allele. Results from this IPD meta-analysis implicate other genetic,
stochastic, and/or environmental factors in the susceptibility to rheumatoid
nodules.
----------------------------------------------------
[16]
TÍTULO / TITLE: - Dendritic cells in
immunity and tolerance-do they display opposite functions?
REVISTA
/ JOURNAL: - Immunity 2003 Jul;19(1):5-8.
AUTORES
/ AUTHORS: - Moser M
INSTITUCIÓN
/ INSTITUTION: - Laboratoire de Physiologie Animale,
Institut de Biologie et Medecine Moleculaires, Universite Libre de Bruxelles,
6041, Gosselies, Belgium. mmoser@ulb.ac.be
RESUMEN
/ SUMMARY: - It was recently proposed that cells of the
dendritic family not only control immunity but also maintain tolerance to
self-antigens, two complementary functions that would ensure the integrity of
the organism in an environment full of pathogens. As they express a variety of
receptors that specifically recognize microbial products, DCs are able to
discriminate between self and nonself and may therefore enable the immune
system to mount potent effector activity to pathogens while silencing
self-reactive lymphocytes. N.
Ref:: 22
----------------------------------------------------
[17]
TÍTULO / TITLE: - Chronic graft-vs-host
disease.
REVISTA
/ JOURNAL: - JAMA. Acceso gratuito al texto completo.
●●
Enlace a la Editora de la Revista http://jama.ama-assn.org/search.dtl
●●
Cita: JAMA: <> 2003 Nov 19;290(19):2599-603.
●●
Enlace al texto completo (gratuito o de pago) 1001/jama.290.19.2599
AUTORES
/ AUTHORS: - Bhushan V; Collins RH Jr
INSTITUCIÓN
/ INSTITUTION: - Hematopoietic Cell Transplantation
Program, Department of Internal Medicine, University of Texas Southwestern
Medical Center, Dallas 75390-8852, USA.
N. Ref:: 26
----------------------------------------------------
[18]
TÍTULO / TITLE: - Genetic control of MHC
class II expression.
REVISTA
/ JOURNAL: - Cell 2002 Apr;109 Suppl:S21-33.
AUTORES
/ AUTHORS: - Ting JP; Trowsdale J
INSTITUCIÓN
/ INSTITUTION: - Department of Microbiology and Immunology
and The Lineberger Comprehensive Cancer Center, University of North Carolina,
Chapel Hill, NC 27599, USA. panyun@med.unc.edu
RESUMEN
/ SUMMARY: - The presentation of peptides to T cells by
MHC class II molecules is of critical importance in specific recognition by the
immune system. Expression of class II molecules is exquisitely controlled at
the transcriptional level. A large set of proteins interact with the promoters
of class II genes. The most important of these is CIITA, a master controller
that orchestrates expression but does not bind directly to the promoter. The
transcriptosome complex formed at class II promoters is a model for induction
of gene expression. N.
Ref:: 108
----------------------------------------------------
[19]
TÍTULO / TITLE: - Interferon-gamma
reduces interleukin-4- and interleukin-13-augmented transforming growth
factor-beta2 production in human bronchial epithelial cells by targeting Smads.
REVISTA
/ JOURNAL: - Chest. Acceso gratuito al texto completo a
partir de 1 año de la fecha de publicación.
●●
Enlace a la Editora de la Revista http://www.chestjournal.org/
●●
Cita: Chest: <> 2003 Mar;123(3 Suppl):372S-3S.
AUTORES
/ AUTHORS: - Wen FQ; Liu XD; Terasaki Y; Fang QH;
Kobayashi T; Abe S; Rennard SI
INSTITUCIÓN
/ INSTITUTION: - Pulmonary and Critical Care Medicine
Section, University of Nebraska Medical Center, Omaha, NE 68198-5125, USA. N. Ref:: 0
----------------------------------------------------
[20]
TÍTULO / TITLE: - When the lymphocyte
loses its clothes.
REVISTA
/ JOURNAL: - Immunity 2003 Apr;18(4):453-7.
AUTORES
/ AUTHORS: - Nekrep N; Fontes JD; Geyer M; Peterlin BM
INSTITUCIÓN
/ INSTITUTION: - Institute of Biochemistry, Medical Faculty
of the University of Ljubljana, Slovenia.
RESUMEN
/ SUMMARY: - The type II bare lymphocyte syndrome (BLS)
or major histocompatibility complex class II (MHCII) deficiency is a severe
combined immunodeficiency (SCID) that is characterized by the absence of
constitutive and inducible expression of MHCII determinants on immune cells.
Four complementation groups of BLS have been defined, and they result from
mutations in DNA-bound activators and the coactivator for MHCII transcription.
Recently, all complementation groups of BLS patients have been accounted for.
Studies of the syndrome and specific mutations reveal important lessons for the
genetics of the immune response. N.
Ref:: 35
----------------------------------------------------
[21]
TÍTULO / TITLE: - Ex vivo selection of
recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for
the control of graft-versus-host disease after allogeneic hematopoietic
stem-cell transplantation.
REVISTA
/ JOURNAL: - Transplantation 2004 Jan 15;77(1
Suppl):S32-4.
●●
Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000106470.07410.CA
AUTORES
/ AUTHORS: - Trenado A; Fisson S; Braunberger E;
Klatzmann D; Salomon BL; Cohen JL
INSTITUCIÓN
/ INSTITUTION: - Biologie et Therapeutique des Pathologies
Immunitaires, Hopital Pitie-Salpetriere, Paris, France.
RESUMEN
/ SUMMARY: - Allogeneic hematopoietic stem-cell
transplantation (HSCT) is the treatment of choice for many malignant and
nonmalignant hematologic disorders. Donor T cells present in the hematopoietic
stem-cell transplant improve engraftment and immune reconstitution and
contribute to the graft-versus-leukemia effect, but are also responsible for
the life-threatening graft-versus-host disease (GVHD). CD4(+)CD25(+)
immunoregulatory T cells, which play a pivotal role in preventing
organ-specific diseases, can also modulate GVHD if administered in equal
numbers of T cells at the time of grafting. In this article, the authors
describe a procedure of ex vivo selection and expansion of regulatory T cells
specific for recipient-type alloantigens. These expanded regulatory T cells
controlled GVHD. Their therapeutic use in HSCT should allow specific
suppression of the activation of donor alloreactive T cells involved in GVHD
while preserving the beneficial effects of other T cells. N. Ref:: 27
----------------------------------------------------
[22]
TÍTULO / TITLE: - Hemochromatosis gene
modifies course of hepatitis C viral infection.
REVISTA
/ JOURNAL: - Gastroenterology 2003 May;124(5):1509-23.
AUTORES
/ AUTHORS: - Pietrangelo A
INSTITUCIÓN
/ INSTITUTION: - Department of Internal Medicine, Centre
for Hemochromatosis and Metabolic Liver Diseases, University of Modena and
Reggio Emilia, Modeno, Italy. antonello@unimore.it N. Ref:: 161
----------------------------------------------------
[23]
TÍTULO / TITLE: - T cell receptor-MHC
interactions up close.
REVISTA
/ JOURNAL: - Cell 2001 Jan 12;104(1):1-4.
AUTORES
/ AUTHORS: - Hennecke J; Wiley DC
INSTITUCIÓN
/ INSTITUTION: - Department of Molecular and Cellular
Biology, Harvard University and Howard Hughes Medical Institute, Cambridge, MA
02138, USA. hennecke@crystal.harvard.edu N. Ref:: 18
----------------------------------------------------
[24]
- Castellano -
TÍTULO / TITLE:La ruta de senalizacion
CA++/calcineurina/NFAT en activacion endotelial y angiogenesis: efectos de la
ciclosporina A. CA++/ calcineurin/NFAT signaling in endothelial activation and
angiogenesis: effects od cyclosporin A .
REVISTA
/ JOURNAL: - Nefrologia. Acceso gratuito al texto
completo.
●●
Enlace a la Editora de la Revista http://www.aulamedica.es/nefrologia/
●●
Cita: Nefrologia: <> 2003;23 Suppl 3:44-8.
AUTORES
/ AUTHORS: - Quesada AJ; Redondo JM
INSTITUCIÓN
/ INSTITUTION: - Centro de Biologia Molecular Severo Ochoa,
Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid
y Centro Nacional de Investigaciones Cardiovasculares (CNIC), Sinesio Delgado,
4 28049 Cantoblanco, Madrid. jmredondo@cbm.uam.es N. Ref:: 31
----------------------------------------------------
[25]
TÍTULO / TITLE: - Regulating the immune
response to transplants. a role for CD4+ regulatory cells?
REVISTA
/ JOURNAL: - Immunity 2001 Apr;14(4):399-406.
AUTORES
/ AUTHORS: - Waldmann H; Cobbold S
INSTITUCIÓN
/ INSTITUTION: - Sir William Dunn School of Pathology,
University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom. herman.waldmann@path.ox.ac.uk N. Ref:: 50
----------------------------------------------------
[26]
TÍTULO / TITLE: - A purgative mastery.
REVISTA
/ JOURNAL: - Nature 2001 Aug 16;412(6848):685-6.
●●
Enlace al texto completo (gratuito o de pago) 1038/35089152
AUTORES
/ AUTHORS: - Nossal GJ
INSTITUCIÓN
/ INSTITUTION: - Department of Pathology, University of
Melbourne, Victoria 3010, Australia. N.
Ref:: 3
----------------------------------------------------
[27]
TÍTULO / TITLE: - Dendritic cells in
transplantation—friend or foe?
REVISTA
/ JOURNAL: - Immunity 2001 Apr;14(4):357-68.
AUTORES
/ AUTHORS: - Lechler R; Ng WF; Steinman RM
INSTITUCIÓN
/ INSTITUTION: - Department of Immunology, Division of
Medicine, Hammersmith Hospital, Imperial College School of Medicine, Du Cane
Road, London W12 ONN, United Kingdom. r.lechler@ic.ac.uk N. Ref:: 80
----------------------------------------------------
[28]
TÍTULO / TITLE: - Clinical practice
guidelines for managing dyslipidemias in kidney transplant patients: a report
from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the
National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
REVISTA
/ JOURNAL: - Am J Transplant 2004;4 Suppl 7:13-53.
●●
Enlace al texto completo (gratuito o de pago) 1111/j.1600-6135.2004.0355.x
AUTORES
/ AUTHORS: - Kasiske B; Cosio FG; Beto J; Bolton K;
Chavers BM; Grimm R Jr; Levin A; Masri B; Parekh R; Wanner C; Wheeler DC;
Wilson PW
RESUMEN
/ SUMMARY: - The incidence of cardiovascular disease
(CVD) is very high in patients with chronic kidney (CKD) disease and in kidney
transplant recipients. Indeed, available evidence for these patients suggests
that the 10-year cumulative risk of coronary heart disease is at least 20%, or
roughly equivalent to the risk seen in patients with previous CVD. Recently,
the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative
(K/DOQI) published guidelines for the diagnosis and treatment of dyslipidemias
in patients with CKD, including transplant patients. It was the conclusion of
this Work Group that the National Cholesterol Education Program Guidelines are
generally applicable to patients with CKD, but that there are significant
differences in the approach and treatment of dyslipidemias in patients with CKD
compared with the general population. In the present document we present the
guidelines generated by this workgroup as they apply to kidney transplant
recipients. Evidence from the general population indicates that treatment of
dyslipidemias reduces CVD, and evidence in kidney transplant patients suggests
that judicious treatment can be safe and effective in improving dyslipidemias.
Dyslipidemias are very common in CKD and in transplant patients. However, until
recently there have been no adequately powered, randomized, controlled trials
examining the effects of dyslipidemia treatment on CVD in patients with CKD.
Since completion of the K/DOQI guidelines on dyslipidemia in CKD, the results
of the Assessment of Lescol in Renal Transplantation (ALERT) Study have been
presented and published. Based on information from randomized trials conducted
in the general population and the single study conducted in kidney transplant
patients, these guidelines, which are a modified version of the K/DOQI
dyslipidemia guidelines, were developed to aid clinicians in the management of
dyslipidemias in kidney transplant patients. These guidelines are divided into
four sections. The first section (Introduction) provides the rationale for the
guidelines, and describes the target population, scope, intended users, and
methods. The second section presents guidelines on the assessment of
dyslipidemias (guidelines 1-3), while the third section offers guidelines for
the treatment of dyslipidemias (guidelines 4-5). The key guideline statements
are supported mainly by data from studies in the general population, but there
is an urgent need for additional studies in CKD and in transplant patients.
Therefore, the last section outlines recommendations for research.
----------------------------------------------------
[29]
TÍTULO / TITLE: - Disease modifying
therapies in multiple sclerosis: report of the Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology and the MS Council
for Clinical Practice Guidelines.
REVISTA
/ JOURNAL: - Neurology 2002 Jan 22;58(2):169-78.
AUTORES
/ AUTHORS: - Goodin DS; Frohman EM; Garmany GP Jr;
Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S
----------------------------------------------------
[30]
TÍTULO / TITLE: - Hepatic T cells and
liver tolerance.
REVISTA
/ JOURNAL: - Nat Rev Immunol 2003 Jan;3(1):51-62.
●●
Enlace al texto completo (gratuito o de pago) 1038/nri981
AUTORES
/ AUTHORS: - Crispe IN
INSTITUCIÓN
/ INSTITUTION: - The David H Smith Center for Vaccine
Biology and Immunology, Department of Microbiology and Immunology, The
University of Rochester, Rochester, New York 14642, USA. Nick_Crispe@urmc.rochester.edu
RESUMEN
/ SUMMARY: - The T-cell biology of the liver is unlike
that of any other organ. The local lymphocyte population is enriched in natural
killer (NK) and NKT cells, which might have crucial roles in the recruitment of
circulating T cells. A large macrophage population and the efficient
trafficking of dendritic cells from sinusoidal blood to lymph promote antigen
trapping and T-cell priming, but the local presentation of antigen causes
T-cell inactivation, tolerance and apoptosis. These local mechanisms might
result from the need to maintain immunological silence to harmless antigenic
material in food. The overall bias of intrahepatic T-cell responses towards
tolerance might account for the survival of liver allografts and for the
persistence of some liver pathogens. N.
Ref:: 169
----------------------------------------------------
[31]
TÍTULO / TITLE: - Identification of TOR
signaling complexes: more TORC for the cell growth engine.
REVISTA
/ JOURNAL: - Cell 2002 Oct 4;111(1):9-12.
AUTORES
/ AUTHORS: - Abraham RT
INSTITUCIÓN
/ INSTITUTION: - Program in Signal Transduction Research,
Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road,
La Jolla, CA 92037, USA. abraham@burnham.org
RESUMEN
/ SUMMARY: - The Target of Rapamycin (TOR) proteins
function in signaling pathways that promote protein synthesis and cell growth.
In yeast, TOR signaling is regulated by nutrient availability, whereas in
metazoan cells TOR activities may be controlled by both nutrients and growth
factors. The recent identification of novel TOR-interacting proteins has
provided crucial insights into TOR regulation and function. N. Ref:: 20
----------------------------------------------------
[32]
TÍTULO / TITLE: